Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats
- PMID: 9700988
- DOI: 10.1097/00005344-199808000-00013
Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats
Abstract
The ability of hexarelin, a recently synthesized hexapeptide with a strong growth hormone (GH)-releasing activity, or of GH itself to display a protectant activity against postischemic ventricular dysfunction in senescent hearts was studied in 24-month-old male rats. Heart preparations from control (saline-treated) senescent rats, subjected to moderate ischemia, showed at reperfusion: (a) a low recovery of postischemic left ventricular developed pressure (LVDP; 37% of the preischemic values; from 90 +/- 5.7 to 33.5 +/- 3.8 mm Hg; p < 0.01; n = 10) coupled to a substantial increase in coronary perfusion pressure (CPP; 71% over baseline; from 68.3 +/- 5.2 to 116.8 +/- 4.6 mm Hg; p < 0.01; n = 10); (b) a marked increase of creatine kinase (CK) released in the perfusates (6.6-fold increase over preischemic values; from 45 +/- 4 to 298 +/- 25 mU/min/g wet tissue; p < 0.001; n = 10). In vivo administration of hexarelin (80 microg/kg, b.i.d., s.c.) for 21 days resulted in a striking heart protection against reperfusion stunning. In fact, the recovery of LVDP at reperfusion was almost complete (90% of the preischemic values; from 93 +/- 5.8 to 83.7 +/- 5.9 mm Hg; p > 0.05; n = 9), and the increase in coronary resistance was minimal (from 67 +/- 5.8 to 79.7 +/- 6.9 mm Hg; p > 0.05; n = 9). Furthermore, the concentration of CK in the perfusates was increased only twofold (from 45.8 +/- 5.5 to 90 +/- 7.2 mU/min/g wet tissue; p < 0.05; n = 9), with a gradual return toward basal values at the end of reperfusion. The protectant activity of hexarelin was divorced from any detectable alteration of the somatotropic function, as assessed by pituitary GH messenger RNA (mRNA) and plasma insulin-like growth factor I levels. In vivo administration of GH (400 microg/kg b.i.d., s.c.) for the same time lapse resulted in only a partial protectant activity: 55% of LVDP recovery (from 91.5 +/- 6.2 to 50 +/- 3.5 mm Hg; p < 0.01; n = 6); 65% increase of coronary resistance (from 68 +/- 4.3 to 112.2 +/- 5.2 mm Hg; p < 0.01; n = 6); 5.3-fold increase of CK concentrations in heart perfusates on reperfusion (from 43.8 +/- 3.8 to 232 +/- 16 mU/min/g wet tissue; p < 0.001; n = 6). Evaluation of the rate of release of 6-keto-prostaglandin F1alpha (PGF1alpha), the stable metabolite of prostacyclin, in heart perfusates, and assessment of the vasopressor activity of angiotensin II on the coronary vasculature, did not show any change in these parameters among the three experimental groups. Collectively these data indicate that hexarelin displays a strong heart-protectant activity against myocardial stunning in senescent rats. The protection afforded by the peptide is likely due to a direct cardiotropic action and is far greater than that of GH. Neither compound appears able to interfere with the endothelium-dependent relaxant mechanism.
Similar articles
-
Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin.Eur J Pharmacol. 1997 Sep 10;334(2-3):201-7. doi: 10.1016/s0014-2999(97)01178-3. Eur J Pharmacol. 1997. PMID: 9369349
-
Endocrine, metabolic and cardioprotective effects of hexarelin in obese Zucker rats.J Endocrinol. 2000 Sep;166(3):529-36. doi: 10.1677/joe.0.1660529. J Endocrinol. 2000. PMID: 10974647
-
Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency.Cardiologia. 1997 Nov;42(11):1165-72. Cardiologia. 1997. PMID: 9534309
-
Growth hormone-independent cardioprotective effects of hexarelin in the rat.Endocrinology. 1999 Sep;140(9):4024-31. doi: 10.1210/endo.140.9.6948. Endocrinology. 1999. PMID: 10465272
-
Hexarelin, a growth hormone secretagogue, protects the isolated rat heart from ventricular dysfunction produced by exposure to calcium-free medium.Pharmacol Res. 2000 Aug;42(2):129-36. doi: 10.1006/phrs.2000.0665. Pharmacol Res. 2000. PMID: 10887041
Cited by
-
Hexarelin, but not growth hormone, protects heart from damage induced in vitro by calcium deprivation replenishment.Endocrine. 2001 Feb;14(1):109-12. doi: 10.1385/endo:14:1:109. Endocrine. 2001. PMID: 11322492
-
The cardiovascular action of hexarelin.J Geriatr Cardiol. 2014 Sep;11(3):253-8. doi: 10.11909/j.issn.1671-5411.2014.03.007. J Geriatr Cardiol. 2014. PMID: 25278975 Free PMC article. Review.
-
Growth hormone secretagogues modulate the electrical and contractile properties of rat skeletal muscle through a ghrelin-specific receptor.Br J Pharmacol. 2003 Jun;139(3):575-84. doi: 10.1038/sj.bjp.0705284. Br J Pharmacol. 2003. PMID: 12788817 Free PMC article.
-
Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.Br J Pharmacol. 2007 Mar;150(5):567-76. doi: 10.1038/sj.bjp.0707131. Epub 2007 Jan 22. Br J Pharmacol. 2007. PMID: 17245365 Free PMC article.
-
Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue.Endocrine. 2001 Feb;14(1):121-32. doi: 10.1385/endo:14:1:121. Endocrine. 2001. PMID: 11322494
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials